Affitech appoints Dr Keith McCullagh chairman
This article was originally published in Scrip
The Norwegian antibody therapeutics company Affitech has appointed Dr Keith McCullagh non-executive chairman of its board of directors. The company's previous chairman, Oyvin Broymer, will remain as a member of the board. Dr McCullagh was most recently CEO at Santaris Pharma in Denmark.
You may also be interested in...
An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.